Table 1

Recent studies that have looked for an association between colonic polyps or cancers and insulin resistance or type 2 diabetes

AuthorsDateSubjectsaEnd pointsbDesignOdds ratioc
C. L. Bird et al. (17)19961,006 men, women from sigmoidoscopy clinicSerum TG in patients with adenomas, controlsCase-control1.5 (1.0–2.2)
G. E. Eyssen et al. (18)1996Colonoscopy clinicSerum insulin, TG in patients with adenomas, controlsCase-control3.2 (P < 0.01)
E. B. Hu et al. (19)1999118,072 nurses; 7,069 diabetics; 892 cancersIncident colorectal cancer in subjects with diabetes, controlsCohort1.4 (1.1–1.9)
R. Kaaks et al. (20)2000New York University Women’s Health studySerum C-peptide and IGFBPsCohort2.9 (1.3–6.8)
S. Kono et al. (21)19987,637 men; 821 with adenomaGlucose tolerance in sigmoid adenoma patients, controlsCohort1.4 (1.0–2.0)
R. E. Schoen et al. (22)19995,849 men; 102 incident adenomasGlucose tolerance in colorectal cancer patients, controlsCohort2.4 (1.2–4.7)
J. C. Will et al. (23)1999>1,000,000; 15,487 diabetics; 3,218 cancersIncident colorectal cancer in diabetics, controlsCohort1.3 (1.0–1.6)
K. Yamada et al. (24)199883,272; 128 in situ cancersSerum TG of patients with in situ cancers, controlsCase-control3.0 (1.4–6.4)
  • a Number of subjects in study and characteristics.

  • b End-points measured. TG, triglyceride; IGFBPs, insulin-like growth factor binding proteins.

  • c Odds ratio, typical value from publication.